Seeking Alpha

The EMA grants orphan drug designation for Sucampo Pharmaceuticals' (SCMP) retinitis pigmentosa...

The EMA grants orphan drug designation for Sucampo Pharmaceuticals' (SCMP) retinitis pigmentosa treatment unoprostone isopropyl. The FDA has already given the product the same designation and an alternate formulation is FDA approved. (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|